Pharsight

Zetonna patents expiration

ZETONNA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(4 years from now)

Zetonna is owned by Covis.

Zetonna contains Ciclesonide.

Zetonna has a total of 1 drug patent out of which 0 drug patents have expired.

Zetonna was authorised for market use on 20 January, 2012.

Zetonna is available in aerosol, metered;nasal dosage forms.

Zetonna can be used as treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child.

The generics of Zetonna are possible to be released after 01 February, 2028.

Drugs and Companies using CICLESONIDE ingredient

Market Authorisation Date: 20 January, 2012

Treatment: Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child

Dosage: AEROSOL, METERED;NASAL

More Information on Dosage

ZETONNA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic